Download the ESMO 2012 Abstract Book - Oxford Journals

Annals of Oncology
Results: Between Dec 2010 and Apr 2012, ∼1000 pts were enrolled from 35
countries, predominantly Spain (n = 180), Italy (n = 110) and France (n = 101).
Baseline characteristics were available from 677 pts as of 30 Jan 2012. Most pts had
stage III/IV OC (stage I/II/III/IV: 7%/11%/60%/18%). The majority (93%) received
paclitaxel q3w and 94% received BEV at a dose of 15 mg/kg; 14% had received prior
neoadjuvant CT. Baseline characteristics from the entire population of ∼1000 pts will
be reported, together with details of CT and BEV schedules selected.
Conclusions: ROSiA should provide valuable new information on the safety of BEV
for up to 36 cycles and in pts who have received neoadjuvant CT, as well as enabling
extensive translational research.
Disclosure: N. Colombo: NC has received honoraria for advisory boards and speaker
engagements from Roche. F. Selle: FS acts as a Consultant for Roche and PharmaMar.
P. Pautier: PP has served on Advisory Boards for Roche and Ipsen. D. Bollag: DB is an
employee and holds stocks in F Hoffmann-La Roche Ltd. A.M. Oza: AO has received
research funding from Roche. All other authors have declared no conflicts of interest.
979P PREDICTIVE AND PROGNOSTIC ROLE OF SURVIVIN AND P53
EXPRESSION IN PATIENTS WITH ADVANCED OVARIAN
CANCER TREATED WITH NEOADJUVANT CHEMOTHERAPY
A. Ga˛ sowska- Bodnar 1 , L. Bodnar 2 , M. Jerzak 3 , G. Wcisło 2 , M. Cichowicz 4 ,
A. Da˛ bek 4 , W. Kozłowski 4 , C. Szczylik 2 , W. Baranowski 1
1 Department of Gynecology and Gyneacology Oncology, MIlitary Institute of
Medicine, Warsaw, POLAND, 2 Department of Oncology, Military Institute of
Medicine, Warsaw, POLAND, 3 Department of Gyneacology and Gyneacology
Oncology, MIlitary Institute of Medicine, Warsaw, POLAND, 4 Department of
Pathology, Military Institute of Medicine, Warsaw, POLAND
Background: Qualification of patients with advanced ovarian cancer (AOC) to
treatment with primary or interval debulking surgery (IDS) is the subject of
controversy. The aim of this study was to assess the expressions of selected proteins of
apoptosis to the effects of neoadjuvant chemotherapy (NAC) in patients with AOC.
Material and methods: We evaluated 60 consecutive patients with AOS (FIGO stage
IIIC-IV) treated with NAC, retrospectively. Formalin-fixed, paraffin-embedded tissue
specimens were immunohistochemically stained for expression of p53 and survivin in
patients given platinum-based NAC undergoing IDS. The expression of survivin was
adopted dichotomization by the median expression of the protein found total score
(TS) equals 2. For low expression of survivin was TS ≤ 2, while high total score TS> 2
The positive and negative expression of p53 were used to dichotomization study group.
Results: Median age of 60 patients was 60 years. The optimal IDS was achieved in
69.1% (38/55). We observed significant difference in the percentage of stained nuclei
(PS, p = 0.0002), the intensity of staining (IS, p = 0.0003) and TS (p = 0.0001) by
comparing the expression of survivin in tumor tissue taken before and after NAC. The
expression of p53 in tumor tissue before and after NAC was observed and significant
difference was in PS, (p = 0.0424). There were no statistically significant difference in
IS and the TS. Expression of survivin and p53 was not related to the results of IDS.
Survivin expression was a prognostic factor in AOC patients treated with NAC (p =
0.0484). Expression of survivin and p53 proteins was not a predictor factor in AOC
patients. Adverse factors affecting the PFS for AOC patients treated with NAC were:
lack of optimal IDS and the lack of an objective response by RECIST criteria
(respectively HR was 3.93 (95% CI, 2.07-7.46, p